| Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | |
| | |
MedLine Citation:
|
PMID: 3888599 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ceftizoxime is a 'third generation' cephalosporin administered intravenously or intramuscularly. Like other third generation cephalosporins it has a wide spectrum of in vitro activity against Gram-positive and Gram-negative bacteria, is particularly active against Enterobacteriaceae (including beta-lactamase-positive strains), and is resistant to hydrolysis by beta-lactamases. However, the third generation cephalosporins are less active than earlier cephalosporins against staphylococci and so could not be considered the drugs of choice. Like many currently available third generation cephalosporins, ceftizoxime has limited activity against Pseudomonas aeruginosa, and thus cannot be recommended as sole treatment of known or suspected non-urinary tract pseudomonal infections. Similarly, although favourable clinical results have been obtained in patients treated with ceftizoxime for infections caused by mixed aerobic/anaerobic organisms (such as intra-abdominal, and obstetric and gynaecological infections), the relatively low in vitro activity of ceftizoxime (in common with most other third generation cephalosporins) against Bacteroides fragilis and enterococci may restrict its usage in situations where these organisms are the suspected or proven pathogens. Ceftizoxime appears to be similar in efficacy to several other cephalosporins in lower respiratory tract infections in elderly and/or debilitated patients, and in chronic and/or complicated urinary tract infections, 2 clinical situations in which third generation cephalosporins may have a major role. Ceftizoxime is also effective clinically and bacteriologically in skin, soft tissue, bone and joint infections, septicaemia/bacteraemia, meningitis and neonatal infections. However, a few large, well designed clinical comparisons of efficacy with aminoglycosides are needed before ceftizoxime can be recommended as an alternative in patients in whom potential aminoglycoside toxicity is a concern. Single intramuscular doses of ceftizoxime appear similar in efficacy to aqueous procaine penicillin G in gonorrhoeae due to nonpenicillinase-producing Neisseria gonorrhoea, and ceftizoxime is also highly effective against penicillinase-producing strains. Although only a few infections have been treated to date, ceftizoxime may be useful in the treatment of gonorrhoea in places where penicillinase-producing strains are common. Thus, ceftizoxime appears to be an effective addition to the growing number of third generation cephalosporins. However, further studies are needed to confirm its relative efficacy compared with other new cephalosporins, in particular cefotaxime.(ABSTRACT TRUNCATED AT 400 WORDS) |
| | |
Authors:
|
D M Richards; R C Heel |
Related Documents
:
|
15200349 - Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. 2962889 - Teicoplanin, a new antibiotic effective against gram-positive bacterial infections of t... 19589649 - Expression by lawsonia intracellularis of type iii secretion system components during i... 4038579 - Aztreonam plus clindamycin as therapy for pelvic infections in women. 10526869 - The role of beta-lactam/beta-lactamase inhibitors in the management of mixed infections. 567939 - The emergence of candidosis. the dominant postmortem cerebral mycosis. 23102749 - A network meta-analysis of antibiotics for treatment of hospitalised patients with susp... 17682039 - Listeriolysin o secreted by listeria monocytogenes into the host cell cytosol is degrad... 17949409 - Lactate dehydrogenase-elevating virus infection at the sensitization and challenge phas... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 29 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1985 Apr |
Date Detail:
|
Created Date: 1985-07-11 Completed Date: 1985-07-11 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: AUSTRALIA |
Other Details:
|
Languages: eng Pagination: 281-329 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Bacterial Agents
/
pharmacology Bacteria / drug effects Bacterial Infections / drug therapy Biotransformation Blood Coagulation / drug effects Cefotaxime / administration & dosage, adverse effects, analogs & derivatives*, metabolism, pharmacology, therapeutic use Ceftizoxime Drug Synergism Ethanol / adverse effects Humans Intestinal Absorption Kidney Diseases / metabolism Kinetics Probenecid / pharmacology Tissue Distribution |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 57-66-9/Probenecid; 63527-52-6/Cefotaxime; 64-17-5/Ethanol; 68401-81-0/Ceftizoxime |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The acute bleeding rectal ulcer
Next Document: Optimum management of postoperative pain.